{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:10:41Z","timestamp":1787069441415,"version":"build-2736575974"},"reference-count":8,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2021,2,2]],"date-time":"2021-02-02T00:00:00Z","timestamp":1612224000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Transfusion"],"published-print":{"date-parts":[[2021,4]]},"abstract":"Abstract<\/jats:title>\n \n Background<\/jats:title>\n Recent case reports have described the efficacy of daratumumab to treat refractory pure red cell aplasia (PRCA) following major ABO mismatched allogeneic hematopoietic stem cell transplantation (HSCT). In this report, we describe the use of daratumumab as a first\u2010line agent for treatment of delayed red blood cell (RBC) engraftment following a major ABO mismatched pediatric HSCT and provide a review of the literature.<\/jats:p>\n <\/jats:sec>\n \n Study Design and Materials<\/jats:title>\n We report on a 14\u2010year\u2010old with DOCK8 deficiency who underwent a myeloablative, haploidentical bone marrow transplant from her major ABO mismatched sister (recipient O+, donor A+) for treatment of her primary immunodeficiency. Despite achieving full donor chimerism, she had delayed RBC engraftment requiring ongoing transfusions. Due to iron deposition, symptomatic anemia, and persistence of anti\u2010A iso\u2010hemagglutinins despite discontinuation of immunosuppression, treatment for delayed RBC engraftment with the CD38\u2010targeted monoclonal antibody daratumumab was selected as a less immunosuppressive agent that could more selectively target iso\u2010hemagglutinin producing plasma cells without causing broad B\u2010cell aplasia.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Clinical effect with daratumumab was demonstrated by reduced iso\u2010hemagglutinin titer, increased reticulocytosis, normalization of her hemoglobin, and transfusion independence. In the 11\u2010month follow\u2010up period to date, no additional transfusions or immunosuppression have been necessary, despite persistence of low\u2010level anti\u2010A iso\u2010hemagglutinin.<\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n Our experience suggests that daratumumab was an effective first\u2010line therapy for delayed RBC engraftment and that earlier consideration for daratumumab in treatment of delayed RBC engraftment may be warranted.<\/jats:p>\n <\/jats:sec>","DOI":"10.1111\/trf.16281","type":"journal-article","created":{"date-parts":[[2021,2,4]],"date-time":"2021-02-04T15:49:06Z","timestamp":1612453746000},"page":"1041-1046","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Daratumumab for delayed\n RBC<\/scp>\n engraftment following major\n ABO<\/scp>\n mismatched haploidentical bone marrow transplantation"],"prefix":"10.1111","volume":"61","author":[{"given":"Bonnie","family":"Yates","sequence":"first","affiliation":[{"name":"Pediatric Oncology Branch Center for Cancer Research, National Cancer Institute, National Institutes of Health Bethesda Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eoghan","family":"Molloy","sequence":"additional","affiliation":[{"name":"Department of Transfusion Medicine NIH Clinical Center Bethesda Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina","family":"Dulau\u2010Florea","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine Hematology Section NIH Clinical Center Bethesda Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raul","family":"Braylan","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine Hematology Section NIH Clinical Center Bethesda Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Hogan","sequence":"additional","affiliation":[{"name":"Pediatric Hematology\/Oncology Stony Brook Children's Stony Brook New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis D.","family":"Hickstein","sequence":"additional","affiliation":[{"name":"Immune Deficiency\u2010 Cellular \u2010Therapy Program National Cancer Institute, National Institutes of Health Bethesda Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra F.","family":"Freeman","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical Immunology and Microbiology National Institute of Allergy and Infectious Diseases North Bethesda Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelley S.","family":"Kalsi","sequence":"additional","affiliation":[{"name":"National Heart Lung and Blood Institute, National Institutes of Health Bethesda Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8474-9080","authenticated-orcid":false,"given":"Nirali N.","family":"Shah","sequence":"additional","affiliation":[{"name":"Pediatric Oncology Branch Center for Cancer Research, National Cancer Institute, National Institutes of Health Bethesda Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,2,2]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1807438"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25515"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-019-0664-4"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13343"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2017.03.016"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-014-0126-0"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01228"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01120-4"}],"container-title":["Transfusion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/trf.16281","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/trf.16281","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/trf.16281","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T08:40:33Z","timestamp":1693557633000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/trf.16281"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,2]]},"references-count":8,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["10.1111\/trf.16281"],"URL":"https:\/\/doi.org\/10.1111\/trf.16281","archive":["Portico"],"relation":{},"ISSN":["0041-1132","1537-2995"],"issn-type":[{"value":"0041-1132","type":"print"},{"value":"1537-2995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,2]]},"assertion":[{"value":"2020-09-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-06","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-02","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}